Biogen’s Dravet And SMA Advances Add Depth To Long Term Story

NodeGuardian · 2026-03-08T03:51:06+00:00

Biogen reported positive clinical results for zorevunersen in Dravet syndrome, showing significant seizure and cognitive benefits. The company also shared new SPINRAZA data and advanced salanersen into Phase 3 trials, highlighting its focus on high-need neurological conditions.

NodeGuardian

2026-03-08 03:51:06

Abstract generation in progress

Biogen (NasdaqGS:BIIB) recently reported promising clinical results for zorevunersen in Dravet syndrome, published in The New England Journal of Medicine, showing durable seizure reductions and cognitive benefits. Concurrently, the company released new high-dose SPINRAZA data for spinal muscular atrophy, including long-term safety and efficacy, and advanced its next-generation SMA candidate, salanersen, into Phase 3 trials. These developments reinforce Biogen’s focus on high-unmet-need neurology niches and provide additional insights for investors assessing its pipeline and risk profile.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes